H.C. Wainwright raised the firm’s price target on Dyne Therapeutics to $55 from $48 and keeps a Buy rating on the shares. The firm says the biomarker and functional outcome data for DELIVER and ACHIEVE is encouraging for potential accelerated approval pathway. The firm believes both the programs have potential for accelerated approval pathway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics price target raised to $43 from $39 at JPMorgan
- Dyne Therapeutics participates in a conference call with JPMorgan
- Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
- Dyne announces new Pompe disease data showing potential of FORCE platform